This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously untreated advanced non-squamous NSCLC |
Tislelizumab + Platinum + Pemetrexed |
Platinum + Pemetrexed |
Primary Endpoint: PFS (IRC) Key Secondary Endpoints: OS, ORR, DoR, safety, QoL |
